Patrick CoxPatrick Cox

Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal, Los Angeles Times, USA Today and Reason Magazine. Patrick has appeared on Crossfire and Nightline, and been written up in The Baltimore Sun and CNBC Magazine. Now, Patrick edits Breakthrough Technology Alert and Technology Profits Confidential, uncovering transformational technologies that offer exponential gains.

Big News Coming in December, and Some “Trading” Advice

I've said this before, but December is going to be a big month for science and several companies in our portfolio. Two of the world's most important startups, Galectin Therapeutics and Arrowhead Research, have scheduled major public disclosures.Galectin Therapeutics, as you surely know by now, dominates the nascent field of glycoscience and carbohydrate-based drugs. One of the greatest scientific surprises of our era is that naturally occurring plant sugars can do simply extraordinary things.

Updates: Galectin Therapeutics, Stereotaxis and Star Scientific

This is a big deal. Galectin Therapeutics practically owns the entire science of carbohydrate-based therapies. Already, we know that their compounds can inhibit the galectin proteins produced by cancers that kill T-cells. Of even more interest to me is the ability of the same compounds to reverse fibrosis in livers, kidneys and other organs. There is currently no other technology that addresses technology, and this company's technology seems to nail it.

International Stem Cell Corp. Progressing Despite Incompetent MSM

Last week, an article by Rob Stein appeared in The Washington Post titled "Scientists Report Possibly Crucial Advance in Human Embryonic Stem Cell Research." Stein, whose credentials include science editor positions at NPR and The Washington Post, describes the use of cloning techniques to turn oocytes, immature eggs, into embryonic cells.

Nobel, Star Scientific, Galectin Therapeutics, Provectus, Cellceutix and More News

I have important news for you about several companies... First, however, I'd like to draw your attention to a paragraph included in the Nobel Prize committee's press release regarding this year's Nobel Prize in physiology or medicine. While the actual prize goes to Bruce A. Beutler, Jules A. Hoffmann and Ralph M. Steinman, this award directly relates to anatabine citrate, the anti-inflammatory developed by Star Scientific.

News From Star Scientific, NanoViricides, Provectus and RXi Pharmaceuticals

This week, the news that will have the biggest impact on your portfolio is the split of RXi Pharmaceuticals into two companies, Galena Biopharma and RXi Pharmaceuticals. This is, essentially, a stock split that will result in your ownership of two companies. One will focus on peptide immunotherapies -- protein-based drugs -- and the other on RNAi-based therapies.

Update: Echo Therapeutics, Protext Mobility and Thoughts on Galectin Therapeutics

Kurtz does not know something that you do, however. Namely, recent biotech breakthroughs in our portfolio are in the process of radically increasing healthy life spans. This makes the Social Security model even less viable. I'm going to write a bit about several of those biotechnologies today.